Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 1, 2018
Reporting Period: Second Quarter 2018 (ended June 30, 2018) and the six months ended June 30, 2018.
This filing serves to incorporate by reference the Company's press release, unaudited interim consolidated financial statements, and Operating and Financial Review regarding the second quarter of 2018.
Key Financial Metrics
The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this Form 6-K cover page. These figures are located in the attached exhibits, specifically:
- Exhibit 99.1: Press Release dated August 1, 2018.
- Exhibit 99.2: Unaudited interim consolidated financial statements (Balance Sheets, Statements of Comprehensive Loss, Changes in Shareholders' Equity, and Cash Flows).
- Exhibit 99.3: Operating and Financial Review and Prospects.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes and Agreements
The filing references a specific material agreement update:
- License Agreement Amendment: Exhibit 10.1 contains Amendment No. 1, dated May 9, 2018, to the License Agreement entered into on March 30, 2018, between Compugen Ltd. and Medimmune, Limited. Certain portions of this exhibit were filed separately under a request for confidential treatment.
Guidance, Outlook, and Risks
Management commentary, outlook, and risk factors for the six months ended June 30, 2018, are detailed in Exhibit 99.3 (Operating and Financial Review and Prospects). This Form 6-K does not summarize the specific content of the outlook or risks but incorporates the full document by reference.
Investor Verification Checklist
- Review Exhibit 99.1 for the official press release summary of Q2 2018 results.
- Examine Exhibit 99.2 for detailed cash flow, liquidity, and loss figures for the six months ended June 30, 2018.
- Analyze Exhibit 10.1 to understand the terms of the amended license agreement with Medimmune, Limited, noting that some details are confidential.
- Consult Exhibit 99.3 for management's discussion of financial prospects and potential risks.